Replies to post #742268 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Do those naysayers from medical field still publish hitting pieces on peer-reviewed journals? They don't. You are dumb and they are not. They know from the Nature paper that massive and sustainable t-cell infiltration into the most difficult tumor site is real. They know also that DCVax-L in combination with poly-iclc can trigger immune memory. They even know that tumor-associated macrophages is the last hurdle to cure GBM. You don't know all these, do you?

See the various types of immune cells activated by DCVax-L? It is fine you want to be a white knight and lecture the longs. But you have to know the science first.
https://www.nature.com/articles/s41467-024-48073-y



Here is the unpublished paper with three naysayers you and your buddy hold in high esteem. What's the conclusion? No survival benefit from neoadjuvant therapy.

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE264695

However, we did not confirm a survival benefit to neoadjuvant pembrolizumab in recurrent glioblastoma. Our new data suggests some patients may exhibit innate resistance to pre-surgical ICI and require other concomitant therapies to sensitize effectively.